 <h1>Naltrexone / oxycodone Side Effects</h1><ul class="nav-tabs nav-tabs-collapse nav-tabs-pill">
<li>Overview</li>
<li><b class="nav-item here">Side Effects</b></li>
<li>Dosage</li>
<li>Interactions</li>
<li>Pregnancy</li>
<li class="nav-more">
More&lt;svg aria-hidden="true" class="ddc-icon ddc-icon-down" focusable="false" height="16" viewbox="0 0 24 24" width="16" xmlns="http://www.w3.org/2000/svg"&gt;&lt;path d="M18.5 7.94L19.56 9 12 16.56 4.44 9 5.5 7.94l6.5 6.5z"&gt;&lt;/path&gt;&lt;/svg&gt;
</li>
</ul><ul>
<li>Managing Side Effects</li>
</ul><p><i>Applies to naltrexone/oxycodone: oral capsule extended release</i></p><h3>General</h3><p>The most frequently reported adverse effects have included nausea, constipation, vomiting, headache, and somnolence.<sup>[Ref]</sup></p><h3>Respiratory</h3><p>Rhinorrhea, chronic bronchitis, dyspnea, and dysphonia were reported in less than 2% of patients.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Oropharyngeal pain, cough</p><p><b>Frequency not reported</b>: Rhinorrhea, chronic bronchitis, dyspnea, dysphonia<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Dyspepsia was reported in less than 2% of patients.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Nausea (up to 20.5%), constipation (up to 14.9%)</p><p><b>Common</b> (1% to 10%): Abdominal pain, diarrhea, dry mouth, nausea </p><p><b>Frequency not reported</b>: Dyspepsia<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>Drug hypersensitivity was reported in less than 2% of patients.  Anaphylaxis and pharyngeal edema have been reported with ingredients contained in this drug.<sup>[Ref]</sup></p><p><b>Frequency not reported</b>: Drug hypersensitivity</p><p><b>Postmarketing reports</b>: Anaphylaxis, pharyngeal edema<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>Tachycardia, palpitations, bradycardia, chest pain, and increased blood pressure were reported in less than 2% of patients.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Peripheral edema</p><p><b>Frequency not reported</b>: Tachycardia, palpitations, bradycardia, chest pain, increased blood pressure</p><p><b>Postmarketing reports</b>: Myocardial ischemia, ventricular fibrillation (with oxycodone overdose)<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Insomnia, depression, restlessness</p><p><b>Frequency not reported</b>: Irritability, abnormal dreams, confusional state, disorientation, decreased libido, drug abuse<sup>[Ref]</sup></p><p>Irritability, abnormal dreams, confusional state, disorientation, decreased libido, and drug abuse were reported in less than 2% of patients.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Dizziness, headache, hypoesthesia, somnolence, tremor</p><p><b>Postmarketing reports</b>: Serotonin syndrome<sup>[Ref]</sup></p><p>Postmarketing reports of serotonin syndrome have been received among patients with concomitant use of opioids and serotonergic drugs.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Rash and urticaria were reported in less than 2% of patients.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Hyperhidrosis, pruritus</p><p><b>Frequency not reported</b>: Rash, urticaria<sup>[Ref]</sup></p><h3>Endocrine</h3><p>Decreased blood testosterone was reported in less than 2% of patients.<sup>[Ref]</sup></p><p><b>Frequency not reported</b>: Decreased blood testosterone</p><p><b>Postmarketing reports</b>: Adrenal insufficiency, androgen deficiency<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Frequency not reported</b>: Dysuria, hematuria<sup>[Ref]</sup></p><p>Dysuria and hematuria were reported in less than 2% of patients.<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Frequency not reported</b>: Anemia, lymphadenopathy<sup>[Ref]</sup></p><p>Anemia and lymphadenopathy were reported in less than 2% of patients.<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Frequency not reported</b>: Abnormal liver function test<sup>[Ref]</sup></p><p>Abnormal liver function test was reported in less than 2% of patients.<sup>[Ref]</sup></p><h3>Metabolic</h3><p>Decreased appetite and gout were reported in less than 2% of patients.<sup>[Ref]</sup></p><p><b>Frequency not reported</b>: Decreased appetite, gout<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Back pain, arthralgia, muscle spasms</p><p><b>Frequency not reported</b>: Myalgia, muscle twitching, musculoskeletal stiffness, arthritis<sup>[Ref]</sup></p><p>Myalgia, muscle twitching, musculoskeletal stiffness, and arthritis were reported in less than 2% of patients.<sup>[Ref]</sup></p><h3>Ocular</h3><p>Increased lacrimation was reported in less than 2% of patients.<sup>[Ref]</sup></p><p><b>Frequency not reported</b>: Increased lacrimation<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Drug withdrawal syndrome, fatigue, hot flush</p><p><b>Frequency not reported</b>: Vertigo, tinnitus, chills, pain, influenza like illness, pyrexia, malaise, intentional surgical and medical procedure misuse<sup>[Ref]</sup></p><p>Vertigo, tinnitus, chills, pain, influenza like illness, pyrexia, malaise, and intentional surgical/medical procedure misuse were reported in less than 2% of patients.<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Troxyca ER (naltrexone-oxyCODONE)." Pfizer U.S. Pharmaceuticals Group, New York, NY. </p><h2>More about naltrexone / oxycodone</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Drug class: narcotic analgesic combinations</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Advanced Reading</li>
</ul><h3>Professional resources</h3><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Pain</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>